News
A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...
Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...
The strong financials and positive sentiment may have contributed to GlaxoSmithKline Pharmaceutical's stock reaching a new 52 ...
The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest.
It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...
Dozens of states are suing to block 23andMe's sale of personal genetic data, citing concerns over customer consent and ...
House Democrats sent letters to the potential buyers of the genetic testing company, asking how they plan to protect customer ...
Blood cancer patients in England will be the first in the world to be offered a 'Trojan horse' drug. Thousands of patients ...
The guideline recommendations advise universal use of hydroxychloroquine, minimizing steroids, and earlier introduction of ...
Multidisciplinary Committee recommends retail price for GSK's cold medicine: Gireesh Babu, New Delhi Friday, June 13, 2025, 08:00 Hrs [IST] The Multidisciplinary Committee (MDC) o ...
IPV Vaccines Market Set to Expand at CAGR of 8.7% Through 2032 | Sanofi Pasteur, GlaxoSmithKline plc
The global IPV vaccines market is estimated to be valued at USD 199.9 Mn in 2025 and expected to reach at USD 358.5 Mn by 2032 With a CAGR of 8.7% during the forecast period (2025-2032). Coherent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results